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Syrian hamster prion protein (PrPc) and a truncated
Syrian hamster prion protein lacking the glycosylphos-
phatidylinositol (GPI) anchor C-terminal signal sequence
(GPI~) were expressed in Chinese hamster ovary cells using
a glutamine synthetase selection and amplification system.
The CHO cell clones expressing the GPI" PrP secreted the
majority of the protein into the media, whereas most of
the PrP produced by clones expressing the full-length
protein with the GPI anchor was located on the cell
surface, as demonstrated by its release upon treatment with
phosphatidylinositol-specific phospholipase C (PIPLC). A
cell clone that expressed the highest levels of full length
PrP was subcloned to obtain clone 30C3-1. PrP from
clone 30C3-1 was shown to be sensitive to proteolysis by
proteinase K and to react with monoclonal and polyclonal
antibodies that recognize native PrPc. The recombinant
PrP migrated as a diffuse band of 19-40 kDa but removal
of the N-linked oligosaccharides with peptide N-glycosidase
F (PNGase F) revealed three protein species of 19, 17 and
15 kDa. The 19 kDa band corresponding to deglycosylated
full-length PrP was quantified and found to be expressed
at a level - 14-fold higher than that of PrPc found in Syrian
hamster brain.
Keywords: Chinese hamster ovary cells/glutamine synthetase
selection and amplification system/prion protein expression
Introduction
Prions are defined as proteinaceous, infectious particles which
contain no nucleic acid and cause neurodegenerative disorders
in a range of different species (Prusiner, 1996). The current
epidemics of bovine spongiform encephalopathy (BSE), or
'mad cow disease', which has resulted in more than 160 000
cattle deaths in Great Britain since 1986, is thought to be
caused by prions initially derived from sheep scrapie
(Wilesmifh et al, 1991). Human prion diseases identified to
date include kuru, Creutzfeldt-Jakob disease (CJD),
Gerstmann-Straussler-Scheinker syndrome (GSS) and fatal
familial insomnia (Gajdusek, 1977; Masters et al, 1981;
Medori et al, 1992). Epidemiological studies suggest that a
new variant form of CJD manifest in Great Britain may be
caused by BSE prions (Will et al, 1996).
The prion protein (PrP) is a normal cellular protein of
unknown function which has been found in both neuronal and
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nonneuronal tissues (Oesch et al, 1985; Kretzschmar et al,
1986; Bendheim et al, 1992; Manson et al, 1992). It is
located on the exterior cell surface and is attached to the
plasma membrane via a glycosylphosphatidylinositol (GPI)
anchor (Stahl et al, 1987, 1990). Fourier transform infrared
(FTIR) and circular dichroism (CD) spectroscopic studies
show that the normal cellular isoform (PrPc) is predominantly
cc-helical in structure with little, if any, P-sheet (Pan et al,
1993; Pergami et al, 1996; Riek et al, 1996). In contrast, the
secondary structure of the pathogenic form (PrPSc) which is
derived from PrPc has less a-helical structure and substantial
amounts of p-sheet (Caughey et al, 1991; Gasset et al, 1993;
Pan et al, 1993; Safar et al, 1993). It is believed that this
conformational transition is the fundamental event in the
conversion of PrPc to PrPSc. To understand better the formation
of PrPSc, it seemed useful to develop a system for producing
large quantities of PrPc, particularly because purification of
PrPc from rodent brain has been difficult (Turk et al, 1988;
Pan et al, 1992; Pergami et al, 1996).
Although the level of PrP mRNA in brain is higher than in
any other tissue in rodents, its abundance is low (Oesch et al,
1985; Kretzschmar et al, 1986). Similarly, the level of PrPc
in brain is higher than in other tissues (Bendheim et al,
1992), but it represents less than 0.1% of the total CNS protein
(Turk et al, 1988; Pan et al, 1992, 1993). Since there is no
natural source of PrPc, we examined many cultured cell types
for PrP synthesis (Scott et al, 1988) and attempted expression
of PrP from vectors transfected into cells. Although many
investigators have reported expression of recombinant PrP,
few of these have produced the PrPc in high amounts.
Milligram quantities of recombinant PrP have been isolated
and purified from bacterial and insect cells (Weiss et al, 1995;
Hornemann and Glochshuber, 1996; Mehlhorn et al, 1996).
In most of the mammalianexpressionsystems where the PrPc
was post-translationally modified by addition of Asn-linked
oligosaccharides and a GPI anchor, the quantity of recombinant
PrPc was low and purification was not reported. In the present
study, we sought to establish a mammalian cell system capable
of generating PrPcat highlevels of expression andwe therefore
chose a glutamine synthetase gene amplification system
(Bebbington et al, 1987).
Chinese hamster ovary (CHO) cells growing in culture
require glutamine for their growth and survival. Glutamine
can either be obtained from the medium or synthesized by the
cells from glutamate and ammonia through catalysis by the
enzyme glutamine synthetase (GS). CHO cells grown in a
selection medium that is glutamine free and contains
methionine sulfoximine (MSX), an inhibitor of GS
(Sanders and Wilson, 1984), do not survive. Specific gene
expression can be achieved by plating the CHO cells in an
MSX selection medium and then transfecting the cells with a
vector that codes for the GS gene along with the foreign
gene of interest (Cockett et al, 1990). Only those cells that
incorporate the vector and express GS at levels sufficiently
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high to overcome the MSX block will survive. Expression of
the foreign gene can be amplified by growing the cells in
successively higher concentrations of MSX. The GS system
has been used to produce a wide variety of recombinant
proteins including HIV-1 envelope gpl20 (Moore etal, 1990),
mb-1 (Brown and Barclay, 1994), a T cell receptor V domain
(Brown and Barclay, 1994), metalloproteinases (Murphy et al,
1991), metalloproteinase inhibitors (Cockett et al, 1990), IgG4
antibody (Bebbington et al, 1992), type-II membrane protein
AMOG/p2 (Gloor et al, 1992), the human thyrotrophin
receptor (Harfst et al, 1992), CD2 (Davis et al, 1993), CD4
(Davis et al, 1990), CD5 (Brown and Barclay, 1994), CD18
(Robinson etal, 1992), CD45 (McCall et al, 1992) and CD48
(van der Merwe et al, 1993). The crystal structures of CD2
(Jones et al, 1992) and CD4 (Brady et al, 1993) have been
obtained from recombinant proteins produced by the GS-
CHO system. Here we report the creation of CHO cell lines
expressing Syrian hamster (SHa) PrP through the use of the
GS selection and amplification system.
Materials and methods
Generation of constructs
The pEE12-27 and pEE14-27 vectors were generated by
removing the polylinker region from pEE12 and pEE14
glutamine synthetase vectors (Celltech, Slough, Berkshire,
UK) via a Hindlll-Bcll digestion and then ligating an adaptor
sequence into the Hindlll-Bcll site. The following DNA
strands were synthesized using a Millipore Expedite 8909
(Perseptive Biosystems, Framingham, MA): ADAP1, 5'
AGCTTGCGTGATCAGCGCTCGAGCGCG 3'; and ADAP2,
5' GATCCGCGCTCGAGCGCTGATCACGCA 3'. The linker
was created by annealing the two DNA strands together. The
open reading frame coding for full length SHaPrP was released
from a p805H4 vector (Scott et al, 1988) via a BamRl-Xhol
digestion and then subcloned into pEE12-27 and pEE14-
27 to generate pEE12-27 SHaPrP and pEE14-27 SHaPrP,
respectively. A carboxy-terminal deletion construct of SHaPrP
(pMSR547) (M.Rogers, unpublished plasmid) containing only
the first 231 nucleotides of the open reading frame and lacking
the GPI signal sequence was removed from the pMSR547
vector via a BgHl-Xhol digestion and then ligated into pEE12-
27 and pEE14-27 to generate pEE12-27-547 and pEE14-27-
547, respectively.
Cloning, selection and amplification
Chinese hamster ovary (CHO) Kl cells (American Type
Culture Collection) grown in GMEM-S medium supple
mented with 10% heat-treated, dialyzed fetal calf serum
(Gibco-BRL) were seeded at 106 cells per 10 cm dish
(Bebbington et al, 1987). After 24 h, each plate of cells was
transfected with 10 ug of either pEE12-27 SHaPrP, pEE14-
27 SHaPrP, pEE12-27-547 or pEE14-27-547 vector, via
calcium phosphate (Gorman, 1985). The cells were then grown
in the presence of 25 uM MSX (Sigma) for 14 days. Sixty
clones were selected and then grown in the presence of 100,
200 or 400 uM MSX for 14 days. The surviving clones
were then analyzed by Western blot analysis to examine PrP
expression (Towbin et al, 1979). Clone 30 was subcloned via
limiting dilution to obtain clone 30C3-1.
Western blot analysis
Cells were grown to confiuency in 10 cm dishes. Prior to
processing for Western blot analysis, the medium was removed
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from the cells, which were then rinsed three times with
phosphate-buffered saline and incubated with UltraCHO
medium (Biowhittaker) while on a rocker at 37°C. After 4 h,
the medium was removed from the cells, passed through a
0.45 uM filter and then precipitated with 10 volumes of
methanol at —20°C for 1 h. The medium was then centrifuged
for 30 min at 4000 g and the pellet resuspended in Laemmli
sample buffer at one tenth of the original volume of medium.
The cells were rinsed three times with phosphate-buffered
saline and then lysed with Laemmli sample buffer (Laemmli,
1970) which contained no P-mercaptoethanol or bromophenol
blue. The lysates were boiled for 5 min and then passed
through a 26 gauge syringe needle five times. Golden Syrian
hamster (LVG:Lak) brains (Charles River Laboratories),
Chinese hamster (Cricetulus griseus) brains (George Yerganian,
Cytogen) and Swiss CD-I mouse brains (Charles River
Laboratories) were homogenized in Laemmli sample buffer
containing no P-mercaptoethanol or bromophenol blue at a
1:9 mass to volume ratio. The homogenate was passed five
times each through 14, 16, 18, 20 and 22 gauge syringe
needles. The protein concentration of the cell lysates and brain
homogenates was measured by BCA Assay (Pierce). Prior to
loading the samples on to 12% polyacrylamide gels, P-
mercaptoethanol and bromophenol blue were added to the
lysates and brain homogenates and then all samples were
boiled for 5 min. Amounts of 30 and 300 ug of cell lysate
protein were loaded on to an SDS-polyacrylamide gel. After
electrophoresis, the samples were electrotransferred to
Immobilon P (Millipore) and then incubated with one of the
following anti-PrP antibodies: R073 (Bendheim et al, 1984),
3F4 (Kascsak et al, 1987), 13A5, PI, P2, P3 (Barry et al,
1985; Barry and Prusiner, 1986) or N-10 (H.Serban, unpub
lished work). All secondary antibodies were conjugated to
horseradish peroxidase and their binding was visualized by
enhanced chemiluminescence (Amersham). The molecular
weight standards used for all blots were myosin (H-chain)
(199.1 kDa), phosphorylase B (106.3 kDa), bovine serum
albumin (69.1 kDa), ovalbumin (43.6 kDa), carbonic
anhydrase (28.4 kDa), P-lactoglobulin (18.9 kDa) and
lysozyme (15.4 kDa); these were obtained from Gibco-BRL.
The molecular weight standards used for Coomassie-stained
polyacrylamide gels were phosphorylase B (101 kDa), bovine
serum albumin (83 kDa), ovalbumin (50.6 kDa), carbonic
anhydrase (35.5 kDa), soybean trypsin inhibitor (29.1 kDa)
and lysozyme (20.9 kDa); these were obtained from Bio-Rad.
Enzymatic treatments
Cell samples treated with proteinase K were first lysed for
5 min at room temperature in 10 mM Tris (pH 7.4), 10 mM
EDTA, 100 mM NaCl, 0.5% Triton X-100, 0.5% deoxycholate
at a volume of 1.0 ml per 10 cm dish. The lysates were
centrifuged at 12 000 g for 45 s. The supernatant was recovered
and its protein concentration determined via BCA assay
(Pierce). Proteinase K (Boehringer Mannheim) was added to
the samples at a ratio of 1 ug of enzyme per 100 ug of protein.
The samples were incubated at 37°C for 45 min. The incubation
was stopped by adding phenylmethylsulfonyl fluoride to a
final concentration of 2 mM and then incubating for an
additional 5 min.
Cell lysates to be treated with PNGase F were processed as
described for the Western blot analysis. A 30 ug amount of
protein was incubated in 40 ul of 20 mM sodium phosphate
(pH 7.0), 25 mM EDTA, 0.6% NP-40, 1% P-mercaptoethanol,
0.1% SDS in the presence of 1200 mU PNGase F (Boehringer
Mannheim). Incubations were carried out for 24 h at 37°C
and then the samples were frozen.
Recombinant phosphatidylinositol-specific phospholipase C
(PIPLC) was isolated from Bacillus cereus (Koke et al,
1991). 30C1-1 cells were used for all the PIPLC studies.
PIPLC treatment was performed on cultured cells by first
removing the media from a 6 cm plate of cells and then rinsing
three times with phosphate-buffered saline; PIPLC was added
at 0.5 units/ml in UltraCHO media. The cells were then
incubated on a rocker for 4 h at 37°C. A duplicate plate
containing the same number of cells was also processed
identically except that it received no PIPLC. The media and
cell lysates were prepared as described above for Western blot
analysis, with the exception that the medium was not passed
through a 0.45 um filter. Aliquots of 2.0% of each sample
were loaded on to a 12% polyacrylamide gel. Following
transfer on to an Immobilon P membrane, the blots were
incubated with R073 antibody and developed as described
above in Western blot analysis.
PIPLC treatment was performed on cell lysates by first
removing the medium from cultured 30C1-1 or N2a cells and
rinsing three times with UltraCHO media. The cells were then
scraped off the plates in UltraCHO media containing
0.16% Triton X-100 (Sigma) and a protease inhibitor cocktail
(Boehringer Mannheim) at a concentration of one inhibitor
tablet per 30 ml of medium, then Dounce homogenized. Each
cell lysate was divided into three equal samples: Laemmli
sample buffer was added to one which was then passed five
times through a 26 gauge needle then boiled for 5 min; the
second was incubated at 37°C for 1 h; PIPLC was added to
the third at a concentration of 0.5 units/ml, and the sample
was incubated at 37°C for 1 h. Following the incubation, the
second and third samples received Laemmli sample buffer and
were processed as described for the first sample. Aliquots of
5.0% of each were loaded on to 12% polyacrylamide gels and
then detected as described above for the PIPLC treatment on
cultured cells. This PIPLC procedure was also used for the
time point assays but with some modifications. Lysates from
two duplicate plates of cells were prepared in medium as
described above. One sample received PIPLC whereas the
other did not; neither sample received protease inhibitors.
Aliquots of 5% of each were removed from both samples at
0, 2, 5, 10, 30 and 60 min. The samples were treated as
described above and then examined via Western blot analysis
using R073 antiserum. Samples visualized via Coomassie
Brilliant Blue staining were processed as described above for
the 30C1-1 or N2a cells except that the incubation was
performed for 4 h.
PrPc quantification
Western blots of serial dilutions of PNGase F-treated 30C3-1
cell lysate and PNGase F-treated brain homogenate were
incubated with 3F4 antibody, which is specific for SHaPrP.
Densitometric scanning of the 19 kDa band from the brain
homogenate and cells was performed using Bioquant OS/2
Image Analysis Software Version 2.50 (R&M Biometrics,
Nashville, TN) on a Grafika computer (DTK). The relative
amounts of PrPc (densitometric units) were plotted versus the
amount of total protein (ug) for both Syrian hamster brain and
30C3-1 cell lysate. For each plot the ratio of the slopes of the
best linear fits to the data was calculated to determine the
relative expression level of PrP in 30C3-1 cells as compared
with Syrian hamster brain.
Recombinant prion protein
Results
Generation of cell clones
To achieve the highest possible expression of PrP, four different
GS vectors expressing PrP were constructed (Figure 1). The
pEE12-27 and pEE14-27 vectors differ in the promoter
regulating the GS gene. SHaPrP and 547 differ in that SHaPrP
contains the entire open reading frame, whereas 547 contains
a carboxy-terminal deletion resulting in the loss of the GPI
addition signal. Thus, PrP encoded by the SHaPrP cDNA
should be attached to the exterior plasma membrane surface
via a GPI achor, whereas PrP expressed from the 547 construct
should be secreted into the medium.
Following calcium phosphate transfection of the four con
structs into CHO-K1 cells, 60 clones were selected in the
presence of 25 uM MSX and then amplified in 100, 200 or
400 uM MSX. Seven clones survived amplification at 100 uM
MSX and one survived at 200 uM (clone 19-200) (Figure 2).
The carboxy-terminal deletion clones received the following
constructs: clones 17, 19 and 19-200, pEE14-27-547; clones
37, 50 and 56, pEE12-27-547. Both clones 29 and 30 received
the full-length construct pEE 12-27-SHa. No clones were
obtained by transfection with the pEE 14-27 SHa vector. The
majority of immunoreactive protein appeared to be in the cell
lysates as opposed to the medium for all clones. However, a
larger percentage of PrP was found in the medium of the
deletion clones as compared with the full-length clones. This
would be expected since the PrP from the deletion clones
should not receive a GPI anchor and thus would be secreted
into the media. It is interesting that there was some PrP in
media taken from clones 29 and 30, which may indicate
autocleavage of PrP from the cell surface.
The major PrP band found in the media from the deletion
clones was observed at a molecular weight of 19 kDa.
Migration of this product to a position lower than native PrPc
from SHa brain (33-35 kDa) could indicate degradation or
lack of glycosylation. PrP found in the cell lysates of clones
29 and 30 appeared as a diffuse band of larger molecular size
ranging from 19 to 40 kDa. The lower range of the band could
represent degradation or processing products. Since equivalent
amounts of total protein were loaded on to the gel, clone 30
appeared to be the highest expressor and was therefore chosen
for further characterization. It was successively subcloned to
obtain clones 30C1-1, 30C2-8 and 30C3-1 (Figure 3). A
comparison of the relative expression levels of the four clones
is shown in Figure 3D.
PrP expression
The expression level of PrP in 30C3-1 cells was compared
with those found in other cell lines that are commonly used
to study PrP (Figure 4). The primary antibody used for the
Western blot analysis was the anti-PrP R073 polyclonal
antiserum, which recognizes PrP in all species tested at
undefined epitopes (Serban et al, 1990). Controls using Syrian
hamster, Chinese hamster and mouse brain homogenates
showed that R073 antiserum recognized PrP with equal
affinity in all three species. The non-transfected CHO cells
appeared to have a very small amount of immunoreactive
protein, none of which was found at the molecular weight of
PrP, 33-35 kDa. A mouse neuroblastoma cell line (N2a) and
a Syrian hamster cell line (HaB) both produced PrP, but in
much lower quantities than found in 30C3-1 cells.
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Fig. 1. SHaPrP glutamine synthetase constructs transfected into CHO cells. SHaPrP is the Syrian hamster PrP open reading frame (ORF). SHaPrP, GPI" is
SHaPrP ORF with the C-terminal GPI anchor addition sequence deleted. CMV represents the human cytomegalovirus promoter. SE refers to the SV40 early
promoter. SL denotes the SV40 late promoter. GS refers to glutamine synthetase. AmpR marks the siteof the ampicillin resistance gene. Thesequence of the
linker is given in the Methods section.
Biochemical and immunological characterization of
recombinant PrP
The immunoreactivity of the recombinant PrP against a series
of antibodies that recognize the native PrPc found in brain
was examined. A comparison of the immunoreactivities of
SHa brain homogenate, non-transfected CHO cell lysate and
30C3-1 cell lysate by Western blot analysis was made using
the following antibodies: N-10 (which recognizes PrPc in all
species tested), 13A5 (which recognizes Syrian hamster PrPc),
PI (specific for the N-terminus of PrP 27-30), P2 (specific for
the N-terminus of PrPc) and P3 (specific for the C-terminus
of PrPc) (Figure 5). The diffuse band corresponding to the
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recombinant PrP from the 30C3-1 cells was seen with all
five antibodies, and no PrP was seen in the non-transfected
CHO cells.
Proteinase K treatment showed that PrP from 30C3-1 cell
lysate was sensitive to proteolytic digestion (Figure 6A), as
was also the case with PrPc from SHa brain homogenate.
PNGase F treatment of SHa brain homogenate resulted in a
shifting of the three PrP bands from 33, 27 and 19 kDa to a
single band at 19 kDa (Figure 6B). By comparison, PNGase
F treatment of 30C3-1 cell lysate produced three major bands,
the most intense of which was at the same position as the
deglycosylated PrPc from brain (19 kDa). The other two 30C3
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Fig. 2. Western blot of media and cell lysates from clones expressing
SHaPrP. Lane 1, 30 ug SHa brain homogenate; lanes 2 and 3, clone 17;
lanes 4 and 5, clone 19; lanes 6 and 7, clone 19-200; lanes 8 and 9, clone
37; lanes 10 and 11, clone 50; lanes 12 and 13, clone 56; lanes 14 and 15,
clone 29; lanes 16 and 17, clone 30. The odd-numbered lanes contain 30 ug
of cell lysate protein. The even-numbered lanes contain media
corresponding to 300 ug of cell lysate protein. The blot was incubated with
R073 antiserum.
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Fig. 3. Western blots of subclones from clone 30 incubated with R073
antiserum. (A) The first generation. Lanes 1 and 2, subclone 30C1-1; lanes
3 and 4, subclone 30C1-2; lanes 5 and 6, subclone 30C1-3. (B) The second
generation. Lanes 1 and 2, subclone 30C2-1; lanes 3 and 4, subclone 30C2-
2; lanes 5 and 6, subclone 30C2-3; lanes 7 and 8, subclone 30C2-4; lanes 9
and 10, subclone 30C2-5; lanes 11 and 12, subclone 30C2-6; lanes 13 and
14, subclone 30C2-7; lanes 15 and 16, subclone 30C2-8; lanes 17 and 18,
subclone 30C2-9. (C) The third generation. Lanes 1 and 2, subclone 30C3-
1; lanes 3 and 4, subclone 30C3-2; lanes 5 and 6, subclone 30C3-3; lanes 7
and 8, subclone 30C3-4; lanes 9 and 10, subclone 30C3-5; lanes 11 and 12,
subclone 30C3-6; lanes 13 and 14, subclone 30C3-7; lanes 15 and 16,
subclone 30C3-8. For each of the above, the even-numbered lanes contain
30 ug of cell lysate protein. The odd-numbered lanes contain media
corresponding to 300 ug of cell lysate protein. (D) Western blot comparison
of clone 30 with the highest expressing subclones, incubated with R073
antiserum. Lane 1, clone 30; lane 2, clone 30C1-1; lane 3, clone 30C2-8;
lane 4, clone 30C3-1. 30 ug of cell lysate protein were loaded into each
lane.
Recombinant prion protein
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28.4
Fig. 4. Western blot comparison of clone 30C3-1 with other cell lines
expressing PrP, incubated with R073 antiserum. Lane 1, CHa brain
homogenate; lane 2, SHa brain homogenate; lane 3, Mo brain homogenate;
lane 4, CHO cell lysate; lane 5, HaB cell lysate; lane 6, N2a; lane 7, clone
30C3-1. 30 ug of cell lysate protein were loaded into each lane.
28.4 —
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Fig. 5. Immunoblot of clone 30C3-1. Lanes 1, 4, 7, 10 and 13, SHa brain
homogenate; lanes 2, 5, 8, 11 and 14, CHO cell lysate; lanes 3, 6, 9, 12 and
15, 30C3-1 cell lysate. Lanes 1-3, N-10 antiserum; lanes 4—6, 13A5
antiserum; lanes 7-9 PI antiserum; lanes 10-12, P2 antiserum; lanes 13-15,
P3 antiserum. 30 ug of total protein were loaded into each lane.
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Fig. 6. (A) Western blot of 30C3-1 cell lysate treated with proteinase K.
Lane 1, 30C3-1 cell lysate; lane 2, 30C3-1 cell lysate + proteinase K. (B)
Western blot of SHa brain homogenate and clone 30C3-1 treated with
PNGase F. Lane 1, SHa brain homogenate; lane 2, SHa brain homogenate,
37°C, 24 h; lane 3 SHa brain homogenate + PNGase F, 37°C, 24 h; lane 4,
30C3-1 cell lysate; lane 5, 30C3-1 cell lysate, 37°C, 24 h; lane 6, 30C3-1
cell lysate PNGase F, 37°C, 24 h. For both panels all lanes received 30 ug
of total protein. Blots were incubated with 3F4 antiserum.
bands (17 and 15 kDa) were of a lower molecular weight than
deglycosylated PrPc from brain and most likely represented
degradation or processing products.
TheSHaPrPc expression level of 30C3-1 cells wascompared
with PrPc expression in SHa brain by Western blot analysis
(Figure 7A). Since PrP from the 30C3 cells contained more
than one protein species, both the brain homogenate and cell
lysate were treated with PNGase F and only the 19 kDa
band corresponding to full-length, unglycosylated PrPc was
quantified by densitometric scanning. Plots of the relative
amounts of PrPc (densitometric units) versus the amount of
total protein (ug) for both SHa brain (Figure 7B) and 30C3-1
cell lysate (Figure 7C) are shown. The ratio of the slopes of
the best linear fits was employed to determine that the
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Fig. 7. (A) Western blot quantification of PrP in 30C3-1 cells. Lanes 1-6,
SHa brain homogenate treated with PNGase F; lanes 7-12, 30C3-1 cell
lysate treated with PNGase F. The following amounts of total protein were
loaded into each lane: lane 1, 7.5; lane 2, 10; lane 3, 15; lane 4, 20; lane 5,
25; lane 6, 30; lane 7, 0.31; lane 8, 0.625; lane 9, 1.25; lane 10, 2.5; lane
11,5; lane 12, 10 ug. The blot was incubated with 3F4 antiserum. (B) Plot
of relative amounts of PrPc in Syrian hamster brain and (C) recombinant
PrP in 30C3-1 cells. The data points are indicated by squares. The straight
lines containing no squares are the best linear fits to the data.
B 12 3 4 5 6
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Fig. 8. Western blots of PrP after cells had been treated with PIPLC. (A)
Western blot of 30C1-1 cells treated with PIPLC. Lane 1, medium from
cells treated with PIPLC; lane 2, cell lysate from cells treated with PIPLC;
lane 3, medium plus cell lysate from cells treated with PIPLC; lane 4,
medium from cells not treated with PIPLC; lane 5, cell lysate from cells not
treated with PIPLC. The blot was incubated with R073 antiserum. (B)
Western blot of 30C1-1 and N2a cell lysates treated with PIPLC. Lane 1,
30C1-1 cell lysate, no treatment; lane 2, 30C1-1 cell lysate at 37°C for 1 h;
lane 3, 30C1-1 cell lysate + PIPLC at 37°C for 1 h; lane 4, N2a cell lysate;
lane 5, N2a cell lysate at 37°C for 1 h; lane 6, N2a cell lysate + PIPLC at
37°C for 1 h. The blot was incubated with R073 antiserum.
expression level of PrP in 30C3-1 cells relative to total protein
was ~14-fold higher than PrPc in SHa brain.
Since full-length PrPc should accept the addition of a GPI
anchor, 30C1-1 cells grown in culture were treated with the
enzyme PIPLC and the medium was examined for released
PrP (Figure 8A). A comparison of medium from cells treated
with PIPLC (lane 1) and medium from an equal number of
cells not treated with PIPLC (lane 4) clearly showed that
PIPLC treatment of the cultured cells resulted in the release
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of PrP into the medium. Subsequent examination of the cell
lysate made from the PIPLC-treated cells (lane 2) showed that
there was still some PrP remaining, but the majority was
released, as was evidenced by comparison with cell lysate
from non-treated cells (lane 5). However, the total PrP in the
media and lysate of the PIPLC-treated cells (lane 3) was
considerably less than that in the lysate from cells not treated
with PIPLC (lane 5).
To address the possibility that extensive PrP loss might have
occurred during the processing of the medium, 30C1-1 cell
lysate was treated directly with PIPLC (Figure 8B). 30C1-1
cells were lysed in the presence of a cocktail of protease
inhibitors and were either loaded directly on to a gel (lane 1)
or incubated for 1 h at 37°C in the absence of (lane 2) or the
presence of PIPLC (lane 3). Although the PIPLC was added
directly to the cell lysate and the lysate was loaded directly
on to a gel after incubation, much of the PrP disappeared.
Similar results were obtained with N2a cell lysates. N2a cell
lysate incubated for 1 h at 37°C in the absence of (lane 5) or
the presence of PIPLC (lane 6) also showed a disappearance
of PrP relative to untreated N2a cell lysate (lane 4). As with
the 30C1-1 cell lysate, protease inhibitors were added to all
the N2a cell lysates.
To explore the notion of protease activity being responsible
for the disappearanceof PrP,30C1-1 cell lysates were incubated
for varying periods of time with PIPLC in the absence of any
protease inhibitors and then visualizedby Westernblot analysis.
A comparison of the treated versus the non-treated samples
showed that even at the earliest measurable times, PrP was
starting to disappear from the PIPLC-treatedcell lysates (Figure
9A). When the same blot was exposed to film for a longer
period of time (60 versus 1 min), no new bands possibly
corresponding to intermediate degradation products were
detected (Figure 9B). To address the issue of general protein
degradation, 30C1-1 cell lysate processed as described for
Figure 9 was subjected to gel electrophoresis then visualized
using Coomassie Brilliant Blue (Figure 10A). No differences
could be seen between the untreated cell lysate (lane 1), lysate
receiving no PIPLC but incubated at 37°C (lane 2) and cell
lysate incubated at 37°C in the presence of PIPLC (lane 3).
An alternative explanation to protease activity is that the
recombinant PrP undergoes conformational changes upon GPI
anchor removal and may no longer be recognized by R073
antibody. To test this hypothesis, PIPLC-treated cell lysate was
incubated with different antisera (Figure 10B). A comparison of
3F4 antibody incubated with PIPLC-treated cell lysate (lane
3) versus non-treated lysate (lanes 1 and 2), 13A5 antibody
incubated with treated lysate (lane 6) versus non-treated lysate
(lanes 4 and 5) and N-10 polyclonal sera incubated with treated
lysate (lane 9) versusnontreatedlysates (lanes7 and 8) showed
a decrease in the amount of PrP being detected with all three
antibodies. Since all antisera tested displayed large decreases
in reactivity with the PIPLC-treated cell lysates, it is unlikely
that the disappearance of PrP is due to lack of antibody
recognition.
Discussion
A conformational change in the structure of PrP seems to be
the fundamental event underlying the prion diseases (Pan et al,
1993). As such, structural studies of PrP are of utmost
importance in deciphering the process whereby PrPc is trans
formed into PrPSc. Although the level of PrPc in rodent brain
is high compared with that in other tissues, it still represents
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Fig. 9. Western blot of 30C1-1 cell lysate treated with PIPLC for various
periods of time. Lysates were incubated at 37°C for the following periods of
time: lanes 1 and 2, 0 min; lanes 3 and 4, 2 min; lanes 5 and 6, 5 min;
lanes 7 and 8, 10 min; lanes 9 and 10, 30 min; lanes 11 and 12, 60 min.
Samples in odd-numbered lanes received no PIPLC. Samples in even-
numbered lanes received PIPLC. The blot was incubated with R073
antiserum. For (A) the film exposure time was 1 min and for (B) the blot
was exposed to film for 1 h.
20.9 —
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Fig. 10. (A) Coomassie Brilliant Blue-stained gel of 30C1-1 cell lysate
treated with PIPLC. Lane 1, 30C1-1 cell lysate, no treatment; lane 2, 30C1-
1 cell lysate at 37°C for 4 h; lane 3, 30C1-1 cell lysate + PIPLC at 37°C
for 4 h. (B) Western blot analysis of 30C1-1 cell lysate treated with PIPLC.
Lanes 1, 4 and 7, 30C1-1 cell lysate, no treatment; lanes 2, 5 and 8, 30C1-1
cell lysate, 37°C, 1 h; lanes 3, 6 and 9, 30C1-1 cell lysates + PIPLC, 37°C,
1 h. The blot was incubated with the following antibodies: lanes 1-3, 3F4
antibody; lanes 4-6, 13A5 antibody; lanes 7*9, N-10 antibody.
Recombinant prion protein
Table I. Summary of systems employed for recombinant PrP expression
Cell type Protein
expressed
Ref.
Escherichia coli SHaPrP" Weiss et al, 1995;
Mehlhorn et al, 1996
MoPrPb Hornemann and Glockshuber,
1996
Spodoptera frugiperda SHaPrPa Scott etal, 1988;
Weiss etal, 1995
Drosophila melanogaster SHaPrP0 Raeber et al, 1995
Xenopus oocytes SHaPrPc Hay etal, 1987
Mouse CI27 MoPrP0 Caughey et al, 1988
Mouse N2a SHaPrP0 Scott et al, 1988;
Chesebro et al, 1993
ChPrP0 Harris et al, 1993;
Gorodinsky and Harris, 1995
Mo/ChPrP° Shyng et al, 1995
Mo/SHaPrPc Chesebro etal, 1993
Mouse ScN2a Mo/ShaPrPc Scott et al, 1992;
Rogers et al, 1993
Mouse NIH3T3 SHaPrP0 Scott et al, 1988;
Kocisko et al, 1994
Mouse Sc+-MNB SHaPrP0
SHa/MoPrPc
MoPrP0
Priolaef a/., 1994
Mouse MNB MoPrP0
Mo/SHaPrPc
Kocisko et al, 1995
Hamster HJC SHaPrP0 Scott etal, 1988
Hamster CHO SHaPrP0 Borchelt etal, 1993
MoPrP0 Lehmann and Harris, 1996
Mo/SHaPrP°
Rat RAT-1 SHaPrP0 Scott et al, 1988
Monkey COS-7 SHaPrP0 Scott et al, 1988
Monkey CV-1 SHaPrP0
SHa/MoPrP°
MoPrP0
Rogers etal, 1991
"Fusion protein formed from PrP and glutathione-S-transferase.
bC-terminal fragment corresponding to mouse residues 111-231.
less than 0.1% of the total CNS protein (Turk et al, 1988;
Pan et al, 1992, 1993). To overcome this difficulty, many
investigators have tried to express recombinant PrPc at high
levels in cultured cells (Table I). The need for such systems
has been emphasized by recent reports on the NMR structure
of fragments of PrP synthesized and labeled in bacteria (Riek
et al. 1996; lames et al, 1997). In one case, a PrP fragment of
111 amino acids likely to correspond to PrPc-II, a degradation
product of PrPc that appears to be formed in caveolae (Pan
et al, 1992), was prepared from Escherichia coli for structural
studies (Hornemann and Glockshauber, 1996). In another case,
a PrP fragment of 142 amino acids that corresponds in sequence
to PrP 27-30, the protease-resistant core of PrPSc (Prusiner
et al, 1984), was prepared from E.coli for structural studies
(Mehlhorn et al, 1996). Such studies with is.co/i-derived
proteins suffer from the lack of post-translational modifications
which may substantially alter the structure of PrP. In most of
the mammalian expression systems where the PrPc was post-
translationally modified by addition of Asn-linked oligo
saccharides and a GPI anchor, the quantity of recombinant
PrPc was low and purification was not reported. In the
studies presented here, we chose a glutamine synthetase gene
amplification system to establish a mammalian cell system
capable of generating PrPc at high levels of expression
(Bebbington et al, 1987).
The Asn-linked oligosaccharides of PrPc are thought to
modify the structure of the protein and in turn alter the rate
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at which it is converted into PrPSc (DeArmond et al, 1997).
Differences in the rates of conversion of PrPc into PrPSc
may be responsible for the strain-specific patterns of PrPSc
accumulation (Hecker et al, 1992; DeArmond et al, 1993).
The GPI anchor of PrPc is required for PrPSc formation
(Taraboulos et al, 1995; Vey et al, 1996; Kaneko et al, 1997;
Naslavsky et al, 1997). The anchor directs the trafficking of
PrPc to the caveolae; redirecting PrPc to clathrin coated pits
or preventing its egress to the cell surface by brefeldin A
abolished PrPSc formation in ScN2a cells (Taraboulos et al,
1991). These findings emphasize the importance of post-
translational glycosylation of PrPc with respect to PrPSc
formation. As such, determining the structure of glycosylated
and glycolipidated PrP is of utmost interest. Hence the develop
ment of a mammalian system for the high-level expression of
PrPc as described here should greatly facilitate structural
studies.
To test the involvement of the GPI anchor in the structural
and functional aspects of PrP, we decided to express and
compare the full-length SHaPrP protein and a SHaPrP mutant
that lacked the carboxyl terminal addition site for a GPI moiety
(Rogers et al, 1993). The full-length SHaPrP would receive
its GPI anchor and be deposited on the outer cell surface. In
this cell type, the structure and function of PrPc might be
preserved if they depended upon the presence of the GPI
anchor. Without the GPI anchor, the PrP would not be attached
to the outer cell surface and thus most likely would be secreted
into the medium. An advantage of not having an anchor would
be to facilitate the purification of the recombinant protein.
All of the GPI" clones secreted PrP that was partly of
lower molecular weight than native PrPc, which could be
due to underglycosylation and/or protein degradation. Non-
glycosylation of SHaPrP lacking a GPI anchor has also been
reported for recombinant SHaPrP expressed in NIH 3T3 cells
(Kocisko et al, 1994). We sought to obtain PrP that was
structurally similar to native PrPc, but at higher levels than in
brain. We therefore chose clone 30, which expressed full-
length PrP, and subcloned it to derive clone 30C3-1. In contrast
to GPI" clones, the full-length recombinant PrP protein was
hyperglycosylated and migrated as a diffuse band between 19
and 40 kDa. PNGase F treatment of the 30C3-1 lysate resulted
in three bands of 19, 17 and 15 kDa. The 19 kDa species
corresponded to the correct size of unglycosylated, full-length
PrP and had also been reported to PNGase F-treated PrP in
ScN2a cells (Taraboulos et al, 1990). The 17 and 15 kDa
species may represent degradation products caused by possible
proteases present in the PNGase F (Tarentino et al, 1985;
Taraboulos et al, 1990). Lower molecular weight products
were also seen with the PNGase F-treated ScN2a cells.
Quantification of the 19 kDa band revealed a 14-fold over-
expression of recombinant PrPrelative to PrPcfromSHabrain
homogenate.
Characterization of the GPI anchor of recombinant PrP
revealed some interesting features. PIPLC treatment of the
PrP-expressing CHO cells resulted in the release of the majority
of PrP. These results are similar to those of Lin et al. (1990),
who reported that PIPLC treatment of CHO cells expressing
recombinant T cell antigen receptor released ~90% of the
receptor from the cell surface. The residual cell-associated PrP
may be located inside the cell and thus inaccessible to the
PIPLC. An alternative explanation may be that a subset of
PrP molecules exist that are resistant to PIPLC release due to
acylation of inositol hydroxyl groups (Mayor et al, 1990).
1472
Also, the amounts of PrP in the medium and in the cell lysate
of PIPLC-treated cells were much reduced compared with that
of untreated cells. To rule out the possibility that PrP was
somehow being lost through routine handling of the medium
taken from PIPLC-treated cells, PIPLC was added directly to
tubes containing recombinant CHO cell lysate. Immediately
after the PIPLC incubation, the lysates were loaded directly
on to gels but a loss of PrP was still observed.
The loss of PrP is perplexing but several hypotheses can be
invoked to explain this phenomenon. The first and most obvious
explanation is that protease-induced degradation occurred. This
explanation is unlikely owing to the presence of protease
inhibitors during the PIPLC treatment, but it may not be ruled
out completely. At present, little is known about the protease
that converts full-length PrPc into PrPc-II (Haraguchi et al,
1989; Pan et al, 1992). This protease appears to be present
in caveolae-like domains (CLDs) where PrPc transits as it
begins reentry into the cell (Taraboulos et al, 1995). Had a
protease been responsible for the loss of PrP upon PIPLC
treatment, it was not specific for CHO cells, as evidenced by
results obtained with N2a cell lysates. Also, the protease would
have been specific for PrP since Coomassie Brilliant Blue-
stained gels revealed no differences in the amount of total
cellular protein between PIPLC-treated and untreated cell
lysates. It is not likely that the PIPLC was contaminated with
a protease. Additional studies of PIPLC treatment on the
recombinant CHO cell lysates were conducted using PIPLC
samples purchased from two different commercial sources.
Although these studies were preliminary and were not done
in the presence of protease inhibitors, it is interesting that
these incubations also resulted in the disappearance of the
majority of the PrP (data not shown). A second explanation
for the disappearance of PrP may be that removal of its
diacylglycerol leads to its instability and thereby renders it
susceptible to degradation. However, Western blot analysis of
samples taken from PIPLC treatment of the recombinant CHO
cell lysates at different times showed a gradual disappearance
of PrP without the generation of any new lower molecular
weight products. A third possibility, that the removal of the
GPI anchor may have altered the antibody recognition of PrP,
was examined. Both the two monoclonal antibodies 3F4
and 13A5 (which recognize different epitopes) and the two
polyclonal sera R073 and N-10 displayed large decreases in
reactivity with the PIPLC-treated cell lysates; therefore, this
explanation seems improbable. A fourth and unexplored pos
sibility is that PIPLC-treated PrP was not detected owing to
inefficient electrophoretic transfer on to membranes upon GPI
anchor removal.
The data reported here on recombinant PrP stability and
PIPLC release are particularly notable since the GPI anchor
of PrP is now known to play an important role in PrPSc
formation (Taraboulos et al, 1995; Vey et al, 1996; Kaneko
et al, 1997; Naslavsky et al, 1997). The formation of PrPSc
is thought to occur in CLDs where GPI anchored proteins are
known to congregate (Smart et al, 1995; Vey et al, 1996). In
CLDs, PrPc is either initially degraded by N-terminal proteo
lytic cleavage to generate PrPc-II or it is converted into PrPSc
(Taraboulos et al, 1995). Hence, the production of large
quantities of recombinant PrPc with a mammalian GPI anchor
may prove essential for dissecting the mechanism of PrPSc
formation.
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